Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways

Abstract

Numerous diseases affect the respiratory tract and the aerosol administration has been widely considered as an adapted and non-invasive method for local delivery. This pathway induces a lung concentration and thus also limits, systemic side effects. However, aerosol delivery of active pharmaceutical ingredients represents a real challenge, due to numerous obstacles such as the specific respiratory movement, the presence of mucus or surfactant, and the mucociliary clearance. Nanomedicines, such as liposomes, micelles or nanoparticles, offer the possibility to increase bioavailability and favor intracellular penetration of specific drugs into lung tissue. This review focuses on the description of aerosol formulations and cellular barriers including design, characteristics and progressive adaptation to airways anatomy. Then, aerosolized formulations currently clinically approved, or in clinical trial are summarized according to the encapsulated drug. In a final section, promising aerosol formulations in pre-clinical studies are detailed.

Optimizations of In Vitro Mucus and Cell Culture Models to Better Predict In Vivo Gene Transfer in Pathological Lung Respiratory Airways: Cystic Fibrosis as an Example

“…The droplet size determines the delivery location in pulmonary airways: the smaller the size, the deeper the deposition. The anatomy of the upper and lower airways and the breathing frequency are also key parameters that influence aerosol deposition [21,22]. Nebulization represents the process of transforming a liquid into an aerosol which can reach the respiratory tract (Figure 1B).…”

Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung

“…By directly inhaling drugs, pulmonary bioavailability can be optimized, while minimizing subsequent adverse effects. 3 , 4 However, drug formulation and aerosol deposition are critical obstacles that impede therapeutic efficacy. Nanomaterials offer a solution by altering drug size, solubility, and surface chemistry to become compatible with the pulmonary microenvironment.…”

Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases

“…Local delivery via inhalation is the means of delivering therapeutics and/or other excipients directly into the lungs with their preferential accumulation in specific lung areas or regions, particularly those with afflicted or diseased cells (Kuzmov & Minko, 2015;Lam, Liang, & Chan, 2012;Resnier, Mottais, Sibiril, Le Gall, & Montier, 2016), which is predominantly useful for treating various lung diseases (Roy & Vij, 2010). For the active component(s) to be available in a respirable form, they are delivered in a liquid or solid that is suspended in a gaseous medium to form an aerosol, which is facilitated by different devices such as nebulizers or dry powder inhalers (DPIs) (Rogueda & Traini, 2007;Rubin & Williams, 2014;Ruge, Kirch, & Lehr, 2013;Zhou, Tang, Shui Yee Leung, Gar Yan Chan, & Chan, 2014).…”